Screener
Nuvectis Pharma, Inc. NVCT Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Nuvectis Pharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The source filing: Nuvectis Pharma, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 9:03 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-055318
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| CURRENT LIABILITIES | ||
| Accounts payable | $4,695 | $6,274 |
| Accrued liabilities | 36 | 115 |
| Employee compensation and benefits | 6,447 | 6,907 |
| TOTAL CURRENT LIABILITIES | 11,178 | 13,296 |
| TOTAL LIABILITIES | 11,178 | 13,296 |
| COMMITMENTS AND CONTINGENCIES, see Note 3 | ||
| SHAREHOLDERS’ EQUITY, see Note 4 |
Item 1. Financial Statements
FAQ
- What is Nuvectis Pharma, Inc.'s accrued expenses?
- Nuvectis Pharma, Inc. (NVCT) reported accrued expenses of $6.45M in Q1 2026.
- How has Nuvectis Pharma, Inc.'s accrued expenses changed year-over-year?
- Nuvectis Pharma, Inc.'s accrued expenses increased by 28.0% year-over-year, from $5.04M to $6.45M.
- What is the long-term trend for Nuvectis Pharma, Inc.'s accrued expenses?
- Over 4 years (2021 to 2025), Nuvectis Pharma, Inc.'s accrued expenses has grown at a 164.1% compound annual growth rate (CAGR), from $142K to $6.91M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about Nuvectis Pharma, Inc.'s accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude